- 09.06.2011 Free monthly season ticket to Girls perusing professional/Vocational Course upto Graduation.
- 09.06.2011 Catering service in Rajdhani/Duronto/Shatabdi trains running beyond schedule/running late.
- 08.06.2011 Amendment to CCS (Pension) Rules, 1972 - Notification regarding
Scientists developing treatments for the devastating brain disorder
Creutzfeldt- Jakob Disease (CJD) have unexpectedly blocked the onset of
Alzheimer's disease, the most common cause of dementia.
Researchers said they were "thrilled" at the unexpected discovery that two
antibodies – extensively studied in relation to CJD – may also have an
affect on Alzheimer's disease. Almost 500,000 people a year in the
million worldwide suffer from Alzheimer's.
The finding, published in Nature Communications, represents a "significant
step forward in the battle to develop drugs to treat Alzheimer's disease,"
they say. The lead came from an American study by researchers at
in Alzheimer's disease.
The finding triggered a race by scientists to discover whether antibodies
being developed as a treatment for CJD might also work against Alzheimer's.
Now a study on mice at the Medical Research Council Prion Unit at
toxic substance called "amyloid beta", a protein which accumulates and
becomes attached to the nerve cells in the brain.
Over time, through its interaction with prion proteins, amyloid stops the
nerve cells from communicating, causing memory loss, the distinctive symptom
Professor John Collinge, the director of the MRC Prion Unit at
"There is an urgent need for new drugs which will help to preserve brain
function and prevent memory loss, the symptom which most characterises the
devastating impact of Alzheimer's. We're thrilled that this discovery shows
in mice that these two antibodies which we are developing to treat CJD may
also have a role in treating more common forms of dementia like Alzheimer's
"If these antibody drugs prove to be safe in use to treat CJD we will
consider whether studies in Alzheimer's disease should be carried out."
Professor Dominic Walsh, a co-author of the study from
extracted from human brain, the same material we believe is causing memory
loss in patients with this devastating disease and we identified two
antibodies that could block this effect.
"The use of these specific antibodies is particularly exciting since they
have already undergone extensive pre-clinical testing for use in treating
CJD. Thus a lot of basic work has already been done and could fast-track
these antibodies for use in humans. The next step is further validation in
other disease models of Alzheimer's and then safety trials in humans."
The two antibodies, ICSM 18 and 35, target the prion protein that is
implicated as a cause of CJD. Clinical trials of drugs based on the
antibodies are due to begin in humans next year as a treatment for CJD. If
they are successful, the trials could be repeated for patients with
One in 14 adults over aged 65 and one in six over aged 80 has dementia,
which in most cases is Alzheimer's disease. The incidence is growing as the